ESSENTIAL PHOSPHOLIPID AND GLYCYRRHIZINATE COMBINED DRUGS FOR MANAGING NON-ALCOHOLIC FATTY LIVER DISEASE
An analysis of the results obtained in an open comparative randomized study of efficacy and safety of Essencigliv® (Minskintercaps UE, the Republic of Belarus) in parallel groups comparing with Phosphogliv® (Pharmstandart-Leksredstva JSC, Russia) used for managing patients suffering from non-alcoholic steatohepatitis (NASH) is presented. The study enrolled 72 patients (36 persons were prescribed Essencigliv® and 36 ones - Phosphogliv®. The drugs were administered per os in form of capsules each containing lipoid PPL-400 equivalent to 65 mg of phosphatidylcholine, 35 mg of trisodium glycyrrhizinate (2 capsules 3 times a day with food ingestion). The treatment period was 4 weeks (30±2 days). The study carried out confirmed the Essencigliv® clinical efficacy, safety and tolerance by patients suffering from NASH, sufficient coincidence with the safety and tolerance profile of Phosphogliv® evidencing about the both drugs equality within the clinically allowed limits.